Can We Predict Osimertinib Resistance?

Video

There are certain indicators for patients with lung cancer who may progress on osimertinib.

There are certain characteristics that seem to have an effect on acquired resistance to osimertinib (Tagrisso) for patients with EGFR-positive non-small cell lung cancer (NSCLC), explained Niels Reinmuth, MD, PhD, head of the Thoracic Oncology Department at Asklepios Lung Clinic.

Those who progressed on the agent tended to have genetic amplifications or alterations, or changes in their signaling pathways, such as PI3k or BRAF.

While about 20 to 25% of patients can be molecularly identified, there is still work to be done for the rest of patient population.

Related Videos
Related Content
FDA Approves First ALK Inhibitor for Adjuvant Therapy in Early-Stage NSCLC

FDA Approves First ALK Inhibitor for Adjuvant Therapy in Early-Stage NSCLC

April 18th 2024
Article

Alectinib was approved for the treatment of patients with ALK-positive non-small cell lung cancer after surgical resection.

The Vitals

Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

November 15th 2023
Podcast

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

Less Than Half of Recently Approved Cancer Drugs Show a Clinical Benefit

Less Than Half of Recently Approved Cancer Drugs Show a Clinical Benefit

April 12th 2024
Article

Over the last 5 years, 57% of drugs approved by the FDA for a cancer-related indication did not show a clinical benefit in confirmatory studies.

Oncology Nursing News

A Look Back at 2022 FDA Approvals in Oncology

January 2nd 2023
Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Adagrasib Provides Greater Benefit vs Docetaxel in KRAS G12C–Mutant NSCLC

Adagrasib Provides Greater Benefit vs Docetaxel in KRAS G12C–Mutant NSCLC

April 9th 2024
Article

Compared with docetaxel, adagrasib improved progression-free survival and objective response rate in patients with pretreated KRAS G12C–mutant non–small cell lung cancer.

TTFields Improves Time to Progression in Brain Metastases From NSCLC

TTFields Improves Time to Progression in Brain Metastases From NSCLC

April 8th 2024
Article

Tumor-treating fields significantly improved the time to intracranial progression in patients from the phase 3 METIS trial with brain metastases from non-small cell lung cancer.

© 2024 MJH Life Sciences

All rights reserved.